During the 6th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Saad Usmani, Levine Cancer Institute, Charlotte, US. We asked, Is re-treatment possible with anti-CD38 therapies?
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Is re-treatment possible with anti-CD38 therapies?
Is re-treatment possible with anti-CD38 therapies?
With two anti-CD38 monoclonal antibodies now available in the clinic (daratumumab and isatuximab), Saad Usmani outlines the importance of having data on the efficacy of re-treatment with anti-CD38 therapies. Two clinical trials are ongoing, and results from these trials are needed to answer this question.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox